Fulgent Genetics

Fulgent is excited to exhibit at this year’s Festival of Genomics, Biodata & AI in Boston.

Fulgent can power your programs from Discovery through Development. We offer one of the largest portfolios of genetic tests in the industry (18,000+) and have integrated multiomic and pathology workflows. We operate CLIA/CAP-accredited labs across the US, Australia, and China. Our 6,700-gene CE-marked Clinical Exome panel rounds out our end-to-end offerings.

Whether you're exploring new testing capabilities, looking to improve your turnaround times, or just want to chat about genomics, we’d love to meet you!

📍 Booth #19 | June 3-4

Each year, roughly 73,000 people in the U.S. and 930,000 people worldwide are diagnosed with head and neck squamous cell carcinoma ( ). For more than half, the disease will recur or progress to a metastatic stage, where treatment options remain limited.

We're encouraged to share that the full abstract from our Phase 2 study of FID-007 in combination with cetuximab is now available on the ASCO 2026 website (https://www.asco.org/annual-meeting) as well as Fulgent’s IR site (https://ir.fulgentgenetics.com/news-events/presentations). Interim data show meaningful clinical activity in this hard-to-treat population, with an objective response rate of 60% and a favorable safety profile across both dosing arms.

Diagnostics and therapeutics are two sides of the same mission at Fulgent — developing flexible, affordable solutions that improve the everyday lives of those around us, and bringing us closer to a fully integrated precision medicine company. FID-007 is one piece of that work in oncology.

Read more at:
https://ir.fulgentgenetics.com/news-releases/news-release-details/fulgent-announces-rapid-oral-full-abstract-publication-fid-007

Updated presentation slides will be posted at the start of the rapid oral abstract session on June 1, 4:30pm to 6:00pm CDT, in Hall D1 of McCormick Place, Chicago.